@article{10902/34533,
year = {2024},
url = {https://hdl.handle.net/10902/34533},
organization = {Funding: this study was funded by Sanofi. Acknowledgments: the authors thank the participating patients and their caregivers, the study centers, and the study investigators for their contributions to the study. The authors also thank Honghong Dong, MS, of Sanofi Research & Development, Bridgewater NJ, USA, for her contribution to the statistical analyses for this study, and BioCytex (a Stago Group company) for their contribution to the immunophenotyping analyses. The on-body delivery system was manufactured by Enable Injections, Inc. Medical writing support was provided by S. Mariani, MD, PhD of Envision Pharma Group, funded by Sanofi.},
publisher = {Ferrata Storti Foundation},
publisher = {Haematologica, 2024},
title = {A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma},
author = {Quach, Hang and Parmar, Gurdeep and Ocio San Miguel, Enrique María and Prince, H. Miles and Oriol, Albert and Crowther, Helen and Tsukada, Nobuhiro and Bories, Pierre and Madan, Sumit and Nathwani, Nitya and Sunami, Kazutaka and Semiond, Dorothee and Yu, Disa and Cordero, Paul and Macé, Sandrine and Suzan, Florence and Moreau, Philippe},
}